• Je něco špatně v tomto záznamu ?

Successful treatment of mild to moderate acne vulgaris with Dr Michaels® (also branded as Zitinex®) topical products family: a clinical trial

U. Wollina, M. Tirant, P. Bayer, M. Coburn, P. Anderson, B. Donnelly, T. Kennedy, J. Gaibor, M. Arora, L. Clews, S. Walmsley, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,

. 2016 ; 30 (2 Suppl 3) : 49-54.

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001372

Acne vulgaris is an epidemic inflammatory skin disease of multi-factorial origin, frequently seen in adolescents and often persisting or occurring through to adulthood. Acne vulgaris is a nearly universal skin disease afflicting 79-95% of the adolescent population in westernized societies and is a significant cause of psychological morbidity in affected patients. Despite the various treatment options available for acne, there is still a need for a safe and effective option. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Zitinex®) product family in the treatment of papulo-pustular acne. 25 patients (17 female/8 male), aged 15-22, with a mild to moderate papulo-pustular acne, localized on the face and on the trunk, were included in this study. None of the patients had used any other kind of treatment in the 3 months prior to commencing this study. All of the patients were treated with Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, a cream, PSC 200 and PSC 900 oral supplements. Application time of Dr Michaels® (Zitinex®) products was 12 weeks. The treatment was been evaluated clinically at 0, 4, 8 and 12 weeks. All of the patients showed an improvement in all parameters of their acne (comedones, papules, pustules, hyperpigmentation and scars). The acne lesions and erythema had mostly resolved. The hyperpigmentation and pitted scarring had significantly reduced also, with the skin appearing smoother. The treatment was well tolerated and no side effects have been described. Our study demonstrates that the Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, cream and oral supplements PSC 200 and PSC 900 are an effective therapeutic option for the treatment of moderately severe acne vulgaris. Moreover, it highlights the safety profile of the Dr Michaels® (Zitinex®) product family in a case of acne compared to traditional first-line treatments.

000      
00000naa a2200000 a 4500
001      
bmc19001372
003      
CZ-PrNML
005      
20190308130457.0
007      
ta
008      
190107s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27498658
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Wollina, U $u Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
245    10
$a Successful treatment of mild to moderate acne vulgaris with Dr Michaels® (also branded as Zitinex®) topical products family: a clinical trial / $c U. Wollina, M. Tirant, P. Bayer, M. Coburn, P. Anderson, B. Donnelly, T. Kennedy, J. Gaibor, M. Arora, L. Clews, S. Walmsley, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, F. Novotny, MG. Roccia, GK. Maximov, K. França, T. Lotti,
520    9_
$a Acne vulgaris is an epidemic inflammatory skin disease of multi-factorial origin, frequently seen in adolescents and often persisting or occurring through to adulthood. Acne vulgaris is a nearly universal skin disease afflicting 79-95% of the adolescent population in westernized societies and is a significant cause of psychological morbidity in affected patients. Despite the various treatment options available for acne, there is still a need for a safe and effective option. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Zitinex®) product family in the treatment of papulo-pustular acne. 25 patients (17 female/8 male), aged 15-22, with a mild to moderate papulo-pustular acne, localized on the face and on the trunk, were included in this study. None of the patients had used any other kind of treatment in the 3 months prior to commencing this study. All of the patients were treated with Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, a cream, PSC 200 and PSC 900 oral supplements. Application time of Dr Michaels® (Zitinex®) products was 12 weeks. The treatment was been evaluated clinically at 0, 4, 8 and 12 weeks. All of the patients showed an improvement in all parameters of their acne (comedones, papules, pustules, hyperpigmentation and scars). The acne lesions and erythema had mostly resolved. The hyperpigmentation and pitted scarring had significantly reduced also, with the skin appearing smoother. The treatment was well tolerated and no side effects have been described. Our study demonstrates that the Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, cream and oral supplements PSC 200 and PSC 900 are an effective therapeutic option for the treatment of moderately severe acne vulgaris. Moreover, it highlights the safety profile of the Dr Michaels® (Zitinex®) product family in a case of acne compared to traditional first-line treatments.
650    _2
$a acne vulgaris $x dietoterapie $x terapie $7 D000152
650    _2
$a aplikace lokální $7 D000287
650    _2
$a mladiství $7 D000293
650    12
$a potravní doplňky $7 D019587
650    _2
$a erytém $x dietoterapie $x terapie $7 D004890
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a kůže $x účinky léků $7 D012867
650    _2
$a péče o kůži $x metody $7 D017592
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tirant, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Bayer, P $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Coburn, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Anderson, P $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Donnelly, B $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Kennedy, T $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Gaibor, J $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Arora, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Clews, L $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Walmsley, S $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Hercogová, J $u 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Fioranelli, M $u Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
700    1_
$a Gianfaldoni, S $u Dermatological Department University of Pisa, Pisa, Italy.
700    1_
$a Chokoeva, A A $u Onkoderma - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
700    1_
$a Tchernev, G $u Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
700    1_
$a Novotny, F $u PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
700    1_
$a Roccia, M G $u University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
700    1_
$a Maximov, G K $u Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria.
700    1_
$a França, K $u Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
700    1_
$a Lotti, T $u Chair of Dermatology, University of Rome G. Marconi Rome, Italy.
773    0_
$w MED00008336 $t Journal of biological regulators and homeostatic agents $x 0393-974X $g Roč. 30, č. 2 Suppl 3 (2016), s. 49-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27498658 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190308130812 $b ABA008
999    __
$a ok $b bmc $g 1364069 $s 1039495
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 2 Suppl 3 $d 49-54 $i 0393-974X $m Journal of Biological Regulators & Homeostatic Agents $n J Biol Regul Homeost Agents $x MED00008336
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace